SUNNYVALE, Calif., April 3, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in adoption of its CyberKnife® and TomoTherapy® Systems in Europe, India, the Middle East and Africa (EIMEA).
Accuray has expanded its installed base in the EIMEA region; Accuray radiation therapy systems have been used to treat more than 45,000 patients in EIMEA, further positioning the company as a global leader in precise, innovative radiation oncology.
The World Health Organization (WHO) World Cancer Report 2014 revealed that the cancer burden is growing at an alarming pace, with the number of annual new cancer cases expected to reach 22 million by 2035, a substantial increase from the current rate of 14 million new cases per year.
Europe is a region showing consistent and sustained growth for Accuray, with a high number of treatment centers that have two CyberKnife Systems at the same location, including Erasmus MC - Daniel den Hoed Cancer Center (Rotterdam, Netherlands), Ospedale Civile San Bortolo (Vicenza, Italy) and Centro Diagnostico Italiano (CDI) (Milan, Italy) as examples. Centers with at least one CyberKnife and one TomoTherapy System are also growing, including Oscar Lambret Cancer Center (Lille, France), Antoine Lacassagne Cancer Center (Nice, France), Leon Berard Cancer Center (Lyon, France), Francois Baclesse Cancer Center (Caen, France), Charite University Hospital (Berlin, Germany) and Gliwice University Hospital (Gliwice, Poland) as examples.
Additional 2013 EIMEA growth highlights include:
- The first CyberKnife® M6™ Series installations in France in the public and private sectors (Centre Eugene Marquis, Rennes, and Centre Hartmann, Levallois-Perret)
- The first CyberKnife M6 Series installation in Luxembourg
- The first CyberKnife System installation in Ireland
- The first TomoTherapy® H™ Series installation in Sri Lanka
- The first TomoTherapy installation in Greece (Iatropolis) making it the only center country-wide to offer both CyberKnife and TomoTherapy treatment
- The first TomoTherapy System installation in Russia
"The CyberKnife and TomoTherapy Systems are widely recognized by the global oncology community as precise, innovative tumor treatments covering the full spectrum of radiation oncology cases," said Lionel Hadjadjeba, general manager for EIMEA and senior vice president international business at Accuray. "These installation milestones reflect the increased adoption of our technologies throughout the world as we strive to optimize cancer care and enhance patient quality of life."
"We only make investments that we believe will make a difference in the quality of care we provide to patients, and we have been long-time users of both CyberKnife and TomoTherapy at our center," said Professor Eric Lartigau, M.D., Ph.D., Centre Oscar Lambret, Lille, France. "The number of patients we treat is growing and we trust in these systems to provide the most innovative and versatile treatment solutions to minimize side effects and maximize patient outcomes."
Accuray Incorporated's newest innovations are the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems. Between them, the entire spectrum of radiation therapy needs are covered. The CyberKnife M6 Series offers the ability to maximize the delivery of high-quality, high-dose distributions that can be confidently delivered to the patient with extreme accuracy over a minimum number of treatments. The system's unique ability to track and correct for tumor motion in real-time enables precise delivery of radiation even when the patient or tumor moves during treatment, helping to minimize side effects and maximize patient comfort throughout and after the treatment process.
The TomoTherapy H Series is versatile and efficient, enabling the delivery of highly effective treatment to a wide range of patients and disease types, while minimizing toxicities. The innovative design of the system allows for treatment plans to be developed and delivered quickly. Integrated, daily CT image guidance provides enhanced accuracy ensuring precise delivery of intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
About Accuray Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, the adoption of new technologies, number of patients treated, increase in cancer growth rates, clinical experience, clinical applications, clinical performance, clinical results, patient treatment times and outcomes, market acceptance of the company's products, the trajectory of the company's business, particularly in certain regions, and the company's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 29, 2013, the company's report on Form 10-Q, which was filed on February 7, 2014, and as updated periodically by the company's other filings.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated